View More Recent Stories
-
Adaptive Biotechnologies (ADPT) and NeoGenomics Partner to Expand Access to Personalized Disease Monitoring for Blood Cancer Patients
-
Raymond James Reiterates Market Perform Rating on Neogenomics (NEO) 'in light of the moving parts'
-
Needham on Neogenomics (NEO): 'We view today's sell-off as an overreaction and recommend buying shares on today's weakness'
-
NeoGenomics (NEO) CEO Chris Smith to retire
-
NeoGenomics (NEO): Felicia Williams Joins NeoGenomics Board of Directors
-
BTIG Reiterates Buy Rating on Neogenomics (NEO)
-
NeoGenomics (NEO) Tops Q3 EPS by 4c, provides guidance
-
NeoGenomics (NEO) Receives New York State Approval for Neo Comprehensive Solid Tumor Test
-
Benchmark Reiterates Buy Rating on Neogenomics (NEO)
-
Needham Reiterates Buy Rating on Neogenomics (NEO)
-
NeoGenomics (NEO) Tops Q2 EPS by 3c ; Offers Guidance

